Medicenna Therapeutics Corp.
MDNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807983
No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Medicenna Therapeutics Corp. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 20 | 19 | −1 |
| Shares | 4.28M | 4.50M | +212.4K (+5.0%) |
| Value | $5.47M | $5.41M | −$52.0K (−1.0%) |
New holders (3)
Institutions that held Medicenna Therapeutics Corp. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Great Valley Advisor Group, Inc. | 19,500 | $23.0K | 0.00% |
| Millennium Management LLC | 16,368 | $19.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,464 | $2.00K | 0.00% |
Sold out (4)
Institutions that held Medicenna Therapeutics Corp. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Intact Investment Management Inc. | 73,900 | $117.0K |
| Susquehanna International Group, LLP | 20,861 | $26.0K |
| Newman Dignan & Sheerar, Inc. | 12,915 | $17.0K |
| Steward Partners Investment Advisory, LLC | 1,666 | $2.00K |